Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug-drug interaction

Cancer Chemother Pharmacol. 2015 Dec;76(6):1317-9. doi: 10.1007/s00280-015-2885-6. Epub 2015 Oct 20.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B / genetics
  • ATP Binding Cassette Transporter, Subfamily B / metabolism
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Cytochrome P-450 CYP2C19 / genetics
  • Cytochrome P-450 CYP2C19 / metabolism
  • Drug Interactions
  • Erlotinib Hydrochloride / adverse effects*
  • Erlotinib Hydrochloride / metabolism
  • Female
  • Homozygote
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Middle Aged
  • Pharmacogenetics
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / metabolism
  • Rhabdomyolysis / chemically induced*
  • Rhabdomyolysis / diagnosis
  • Rhabdomyolysis / genetics

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • Protein Kinase Inhibitors
  • Erlotinib Hydrochloride
  • Cytochrome P-450 CYP2C19